Summary of Recommendations

Document Overview

Design and created by Guideline Central in participation with the Centers for Disease Control and Prevention.

Use of the GSK MenACWY-CRM/MenB-4C Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years

Centers for Disease Control and Prevention

Publication Date: Jan 8, 2026

Page Last Updated: May 5, 2026

Clinical Guidance

Shared clinical decision-making for MenB. For healthy persons, MenACWY-CRM/MenB-4C may be administered on the basis of shared clinical decision-making. Providers can refer to previously published considerations for shared clinical decision-making regarding MenB administration.
Interchangeability of vaccine products. MenACWY products are interchangeable, although the same vaccine product is preferred for all doses. However, because MenB products from different manufacturers contain different antigens, they are not interchangeable; existing recommendations for administering MenB products are based on evidence for which only the same manufacturer’s product was administered. All doses of a serogroup B–targeting vaccine administered to an individual person, including booster doses, should be from the same manufacturer. If doses from multiple manufacturers have been administered to the same person, the person should receive a complete series of either manufacturer’s product without counting doses from the other manufacturer as valid . Providers should always check the packaging label to be certain they are administering the intended vaccine product to the recipient.
If MenB doses have been previously received by an individual but the vaccine manufacturer is unknown, an attempt should be made to obtain past immunization records (e.g., from the health care provider or immunization information system [immunization registry]) to ascertain the vaccine brand used for previous MenB doses. If the brand cannot be determined, the series should be restarted with any licensed MenB–targeting vaccine to ensure receipt of a complete MenB series with products from a single manufacturer.
Indavertent administration of MenACWY-CRM/MenB-4C. If MenACWY-CRM/MenB-4C is inadvertently administered when either MenACWY only or MenB only is indicated, the dose can be considered valid if it otherwise would have been a valid administration of MenACWY or MenB.
Dosing intervals. Healthy adolescents and young adults aged 16–23 years who receive a dose of MenACWY-CRM/MenB-4C on the basis of shared clinical decision-making should complete the MenB series with a dose of MenB-4C administered 6 months after the MenACWY-CRM/MenB-4C dose (3). Persons at increased risk for meningococcal disease who receive a dose of MenACWY-CRM/MenB-4C and who are recommended to receive additional doses of MenACWY and MenB <6 months after a dose of pentavalent meningococcal vaccine should receive separate MenACWY and MenB-4C vaccines, rather than MenACWY-CRM/MenB-4C, following recommended intervals. Additional details regarding when doses might need to be administered <6 months apart are available in the Child Immunization Schedule Notes (Meningococcal Serogroup A, C, W, Y Vaccination and Meningococcal Serogroup B Vaccination) and the Adult Immunization Schedule Notes (Meningococcal Vaccination).
MenACWY-CRM/MenB-4C may be used for booster doses among persons at increased risk for meningococcal disease if a booster dose of both MenACWY and MenB are indicated at the same visit. MenACWY-CRM/MenB-4C doses deviating from the licensed 6-month interval can be considered valid for MenACWY or MenB if the timing would otherwise have been valid for that component.

BOX. Meningococcal vaccination recommendations — Advisory Committee on Immunization Practices, United States, 2025

The Advisory Committee on Immunization Practices (ACIP) recommends quadrivalent (serogroups A, C, W, Y) meningococcal conjugate (MenACWY) vaccination* for the following groups:

Healthy persons aged 11–12 years: Routine vaccination with a single dose for all persons aged 11–12 years, with a booster dose at age 16 years
Persons aged ≥2 months who are at increased risk for meningococcal disease: Routine and booster vaccination. (Dosing schedule varies by age and indication; interval for booster doses varies by age.)†
- Persons with certain medical conditions, including anatomic or functional asplenia, HIV infection, and persistent complement component deficiency, and those who use complement inhibitors (e.g., eculizumab or ravulizumab)
- Persons traveling to countries with hyperendemic or epidemic meningococcal disease, including countries in the African meningitis belt or during Hajj
- First-year college students who live in residential housing, if not previously vaccinated
- Military recruits
- Microbiologists routinely exposed to Neisseria meningitidis isolates
- Persons at increased risk during an outbreak of meningococcal disease caused by serogroup A, C, W, or Y

ACIP recommends serogroup B meningococcal (MenB) vaccination§ for the following groups:

Healthy persons aged 16–23 years: Vaccination with a 2-dose MenB series on the basis of shared clinical decision-making, with 16–18 years the preferred age for MenB vaccination
Persons aged ≥10 years who are at increased risk for meningococcal disease: Routine and booster vaccination. (Dosing schedule varies by indication; the first booster dose should be given 1 year after the primary series, with additional boosters every 2–3 years if the risk remains.)
- Persons with certain medical conditions, including anatomic or functional asplenia and persistent complement component deficiency, and those who use complement inhibitors (e.g., eculizumab or ravulizumab)
- Microbiologists routinely exposed to N. meningitidis isolates
- Persons at increased risk during an outbreak of meningococcal disease caused by serogroup B

ACIP recommends pentavalent (serogroups A, B, C, W, and Y) meningococcal (MenABCWY) vaccination¶ for the following groups:

Persons aged ≥10 years for whom MenACWY and MenB are both indicated: Primary series vaccination if MenACWY and MenB would be administered as separate vaccines at the same health care visit
Persons aged ≥10 years who are at increased risk for meningococcal disease who previously received MenABCWY or MenB ≥6 months earlier: Booster vaccination if MenACWY and MenB would be administered as separate vaccines at the same health care visit; if the previous doses included a MenB-FHbp component, MenACWY-TT/MenB-FHbp would be used, whereas MenACWY-CRM/MenB-4C would be used if the previous doses included a MenB-4C component

* Quadrivalent MenACWY vaccines from different manufacturers are interchangeable, although the same vaccine product is recommended for all doses.
† Meningococcal Vaccination | Recommendations of the Advisory Committee on Immunization Practices, United States, 2020
§ MenB vaccines from different manufacturers are not interchangeable. All doses used for the primary series (and booster doses, if applicable) should be from the same manufacturer.
¶ Pentavalent MenABCWY vaccines from different manufacturers are not interchangeable because the MenB components are not interchangeable. If a serogroup B–targeting vaccine has already been administered, subsequent doses should be from the same manufacturer.

Document Overview

Document Title: Use of the GSK MenACWY-CRM/MenB-4C Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years

Authoring Society: Centers for Disease Control and Prevention

Document Publication Date: Jan 8, 2026

Page Last Reviewed/Updated: May 5, 2026

Document Type: Consensus Statement

Country of Publication: United States

Full Text Freely Available: Yes

Full Text Guideline: www.cdc.gov/mmwr/volumes/75/wr/mm7501a2.htm?s_cid=mm7501a2_w

Source Citation: Amin AB, Collins JP, Dong X, Leidner AJ, Loehr J, Moser CA, McNamara LA. Use of the GSK MenACWY-CRM/MenB-4C Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025. MMWR Morb Mortal Wkly Rep. 2026 Jan 8;75(1):7-14. doi: 10.15585/mmwr.mm7501a2. PMID: 41505372; PMCID: PMC12782235.

Document Scope, Criteria, and Use Cases

Document Objectives: Meningococcal disease is a serious bacterial infection caused by Neisseria meningitidis. Serogroups B, C, W, and Y cause the majority of cases of this disease in the United States. These serogroups are targeted by different meningococcal vaccines available in the United States. Two quadrivalent (serogroups A, C, W, and Y) meningococcal conjugate vaccines (MenACWY) (MenACWY-CRM [Menveo, GSK] and MenACWY-TT [MenQuadfi, Sanofi Pasteur]) and two serogroup B meningococcal vaccines (MenB) (MenB-4C [Bexsero, GSK] and MenB-FHbp [Trumenba, Pfizer]) are licensed for use in the United States and recommended by CDC’s Advisory Committee on Immunization Practices (ACIP). Indications for MenACWY and MenB vaccination have not changed since indications for their use were published in 2020. A pentavalent (serogroups A, B, C, W, and Y) meningococcal vaccine (MenABCWY) (MenACWY-TT/MenB-FHbp [Penbraya, Pfizer]) has been licensed and recommended for use since October 2023. On February 14, 2025, the Food and Drug Administration licensed a second pentavalent MenABCWY vaccine (MenACWY-CRM/MenB-4C [Penmenvy, GSK]) for prevention of invasive disease caused by N. meningitidis serogroups A, B, C, W, and Y in persons aged 10–25 years, the same indication for which MenACWY-TT/MenB-FHbp is licensed. On April 16, 2025, ACIP recommended that MenACWY-CRM/MenB-4C may be used when both MenACWY and MenB are indicated at the same visit for 1) healthy persons aged 16–23 years (routine schedule) when shared clinical decision-making favors administration of MenB vaccine and 2) persons aged ≥10 years who are at increased risk for meningococcal disease (e.g., because of persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia). Different manufacturers’ serogroup B–targeting vaccines are not interchangeable; therefore, when MenACWY-CRM/MenB-4C is used, MenB-4C should be used for the other MenB doses. This report summarizes evidence considered for these recommendations and provides clinical guidance for the use of MenACWY-CRM/MenB-4C.

Scope: Prevention

Diseases/Conditions (MeSH)

D008585 - Meningitis, Meningococcal

D022401 - Meningococcal Vaccines

D008585 - Meningitis, Meningococcal

D022401 - Meningococcal Vaccines

Keywords: MenACWY-CRM, Meningococcal, Meningococcal Vaccination

Target Patient Population: Persons Aged ≥10 Years

Inclusion Criteria: Male, Female, Adolescent, Adult, Child, Older Adult

Health Care Settings: Ambulatory

Intended Users: Nurse, Nurse Practitioner, Physician, Physician Assistant

Use of the GSK MenACWY-CRM/MenB-4C Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years

Summary of Recommendations

Recommendations for Use of MenACWY-CRM/MenB-4C

Clinical Guidance

Contraindications and Precautions

BOX. Meningococcal vaccination recommendations — Advisory Committee on Immunization Practices, United States, 2025

Document Overview

Document Scope, Criteria, and Use Cases